Clinical Trial Update: Evaluation of Gixam's Performance in a FIT Negative Population [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Gixam in FIT-negative individuals for colorectal cancer screening; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenoma
• Colorectal Cancer

Drugs mentioned

• Gixam

Snippet

Sponsor: Jubaan Ltd. | Conditions: Colorectal Adenoma, Colorectal Cancer (CRC) | Phase 2 | Status: RECRUITING